[{"data":1,"prerenderedAt":214},["ShallowReactive",2],{"drug-flecainide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":52,"contraindications":105,"warnings":115,"renal":123,"monitoring":124,"interactions":125,"review":126,"examples":129,"atc":144,"iran":146,"links":166,"populations":183,"usApproval":209},"flecainide",1,{"fa":7,"en":8},"فلکائینید","Flecainide","cardiovascular",{"fa":11,"en":12},"ضدآریتمی کلاس IC","Class IC antiarrhythmic",[14],{"name":15,"market":16},"Tambocor","US",[18,19,7],"tambocor","فلکاینید",[21,35,44],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[16],[32],{"source":33,"section":34},"fda-flecainide","How Supplied",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":41,"refs":42},"tab-100","100 mg tablet (scored)",{"amount":39,"unit":28,"perUnit":23,"scored":40},100,true,[16],[43],{"source":33,"section":34},{"id":45,"form":23,"route":24,"label":46,"concentration":47,"markets":49,"refs":50},"tab-150","150 mg tablet (scored)",{"amount":48,"unit":28,"perUnit":23,"scored":40},150,[16],[51],{"source":33,"section":34},[53,72,84],{"id":54,"disease":55,"label":56,"population":59,"type":63,"unit":28,"dose":64,"refs":69},"pafpsvt","atrial-fibrillation",{"fa":57,"en":58},"PAF یا PSVT — ۵۰ mg هر ۱۲ ساعت، افزایش ۵۰ mg دو بار در روز هر ۴ روز، حداکثر ۳۰۰ mg\u002Fروز","PAF or PSVT — 50 mg every 12 h, +50 mg twice daily every 4 days, max 300 mg\u002Fday",{"minAge":60},{"value":61,"unit":62},18,"year","titration",{"dividedDoses":65,"titration":66},2,{"start":39,"increment":39,"incrementEveryDays":67,"max":68},4,300,[70],{"source":33,"section":71},"Dosage and Administration",{"id":73,"disease":74,"label":75,"population":78,"type":63,"unit":28,"dose":80,"refs":82},"psvt","svt",{"fa":76,"en":77},"PSVT — ۵۰ mg هر ۱۲ ساعت (حداکثر ۳۰۰ mg\u002Fروز)","PSVT — 50 mg every 12 h (max 300 mg\u002Fday)",{"minAge":79},{"value":61,"unit":62},{"dividedDoses":65,"titration":81},{"start":39,"increment":39,"incrementEveryDays":67,"max":68},[83],{"source":33,"section":71},{"id":85,"disease":86,"label":87,"population":90,"type":63,"unit":28,"dose":92,"refs":96,"notes":98},"vt","ventricular-arrhythmia",{"fa":88,"en":89},"VT پایدار — ۱۰۰ mg هر ۱۲ ساعت، حداکثر ۴۰۰ mg\u002Fروز (شروع در بیمارستان)","Sustained VT — 100 mg every 12 h, max 400 mg\u002Fday (start in hospital)",{"minAge":91},{"value":61,"unit":62},{"dividedDoses":65,"titration":93},{"start":94,"increment":39,"incrementEveryDays":67,"targetMax":68,"max":95},200,400,[97],{"source":33,"section":71},[99],{"text":100,"refs":103},{"fa":101,"en":102},"با پایش ریتم در بیمارستان شروع شود؛ بیشتر بیماران بیش از ۱۵۰ mg هر ۱۲ ساعت لازم ندارند. افزایش دوز زودتر از هر ۴ روز نه.","Start in hospital with rhythm monitoring; most need no more than 150 mg every 12 h. Increase no more often than every 4 days.",[104],{"source":33,"section":71},[106],{"id":107,"severity":108,"text":109,"refs":112},"ci","block",{"fa":110,"en":111},"بلوک AV درجه ۲ یا ۳، یا بلوک دودسته‌ای بدون پیس‌میکر؛ شوک کاردیوژنیک؛ حساسیت.","Pre-existing 2nd\u002F3rd-degree AV block or bifascicular block without a pacemaker; cardiogenic shock; hypersensitivity.",[113],{"source":33,"section":114},"Contraindications",[116],{"text":117,"refs":120},{"fa":118,"en":119},"هشدار جعبه‌ای: افزایش مرگ‌ومیر پس از MI (CAST)؛ در AF مزمن توصیه نمی‌شود؛ اثر پروآریتمیک.","Boxed warning: excess mortality after MI (CAST); not recommended for chronic AF; proarrhythmic effects.",[121],{"source":33,"section":122},"Warnings",[],[],[],{"status":127,"reviewer":128,"date":128},"unverified",null,[130,134,139],{"regimen":54,"formulation":22,"input":131,"expect":133},{"ageYears":27,"weightKg":132},75,{"perDose":27,"tabletsPerDoseRounded":5},{"regimen":85,"formulation":36,"input":135,"expect":138},{"ageYears":136,"weightKg":137},60,80,{"perDose":39,"tabletsPerDoseRounded":5},{"regimen":73,"formulation":22,"input":140,"expect":143},{"ageYears":141,"weightKg":142},45,70,{"perDose":27,"tabletsPerDoseRounded":5},[145],"C01BC04",{"status":147,"forms":148,"refs":161},"registered",[149,153,157],{"code":150,"en":151,"fa":152},"00536","FLECAINIDE 100MG TAB","قرص فلکائینید ۱۰۰ میلی‌گرم",{"code":154,"en":155,"fa":156},"07909","FLECAINIDE ACETATE 10MG\u002FML AMP","آمپول فلکائینید استات ۱۰ میلی‌گرم \u002F میلی‌لیتر",{"code":158,"en":159,"fa":160},"11913","FLECAINIDE ACETATE 50MG TAB","قرص فلکائینید استات ۵۰ میلی‌گرم",[162],{"source":163,"section":164,"url":165},"darooyab-generic","G-1684\u002FFlecainide","https:\u002F\u002Fwww.darooyab.ir\u002FG-1684\u002FFlecainide",[167,171,175,178,181],{"kind":168,"url":169,"label":170},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=075442","ANDA075442",{"kind":172,"url":173,"label":174},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ee9595d5-08a1-4529-9215-ddc3c7f929c4","FDA Flecainide",{"kind":176,"url":177,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa608040.html",{"kind":179,"url":180,"label":145},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C01BC04",{"kind":182,"url":165,"label":8},"darooyab",{"pregnancy":184,"lactation":193,"pediatric":201},{"level":185,"text":186,"quote":189,"refs":190},"caution",{"fa":187,"en":188},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Pregnancy Category C.",[191],{"source":33,"section":192},"Precautions\u002FWarnings – Pregnancy",{"level":185,"text":194,"quote":197,"refs":198},{"fa":195,"en":196},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Results from a multiple dose study conducted in mothers soon after delivery indicates that flecainide is excreted in human breast milk in concentrations as high as 4 times (with average levels about 2.5 times) corresponding plasma levels; assuming a maternal plasma level at the top of the therapeutic range (1 mcg\u002FmL), …",[199],{"source":33,"section":200},"Precautions\u002FWarnings – Nursing Mothers",{"level":185,"text":202,"quote":205,"refs":206},{"fa":203,"en":204},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of flecainide in the fetus, infant, or child have not been established in double-blind, randomized, placebo-controlled trials.",[207],{"source":33,"section":208},"Precautions\u002FWarnings – Pediatric Use",{"kind":210,"refs":211,"id":170},"ANDA",[212],{"source":33,"section":213},"SPL approval \u002F marketing category",1792115180302]